Responses
Immune cell therapies and immune cell engineering
Original research
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
Compose a Response to This Article
Other responses
No responses have been published for this article.
